Therapeutic lowering of lipoprotein(a): How much is enough?

Atherosclerosis. 2019 Sep:288:163-165. doi: 10.1016/j.atherosclerosis.2019.07.003. Epub 2019 Jul 5.

Author

Florian Kronenberg¹

Affiliation

¹ Institute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Austria. Electronic address: Florian.Kronenberg@i-med.ac.at.

PMID: 31327477
DOI: 10.1016/j.atherosclerosis.2019.07.003

No abstract available

Keywords: Lipid-lowering drugs; Lipoprotein(a).

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Cardiovascular Diseases*
Humans
Lipoprotein(a)*
Proprotein Convertase 9

Substances

Antibodies, Monoclonal, Humanized
Lipoprotein(a)
PCSK9 protein, human
Proprotein Convertase 9
alirocumab